Pharsight

1. Minocin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084802	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)
US9278105	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/vial	16 Oct, 2020	1	22 Jul, 2022	12 May, 2031	Eligible

Strength	Dosage	Availability
EQ 100MG BASE/VIAL	INJECTABLE;INJECTION	Prescription

MINOCIN family patents

2. Vabomere patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561675	November, 2016	Decision	Rempex Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680136	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561675	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US10183034	REMPEX	Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (7 years from now)
US11007206	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US9694025	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US10172874	REMPEX	Pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (7 years from now)
US11376237	REMPEX	Methods of treating bacterial infections	Apr, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN)	Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 2026-08-29

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...

Dosage: POWDER;INTRAVENOUS